SYNTHESIS, ANTICANCER ACTIVITY, MOLECULAR DOCKING STUDY, OF 4,4DICHLORO-1,3-OXAZILIDINE-5-ONE DERIVED FROM ISONIAZID

Breast cancer is considered one of the increasingly serious problems affecting women recently, so many parties are seeking to find effective solutions that reduce its risks. Therefore, the research paper aimed to synthesize hydrazide–hydrazones of isoniazid (T1–T5), which underwent reaction with trichloroacetic acid (TCA), resulting in the synthesis of a series of 4,4-dichloro-1,3-oxazolidine-5-one derivatives (T6–T10) with satisfactory yields. With the use of sophisticated spectroscopic methods such as 13C-NMR, 1H-NMR, and FTIR, the structure of the recently synthesized compounds was thoroughly verified. The compounds were evaluated for their anticancer potential against the MCF-7 breast cancer cell line. Notably, compounds T7 and T9 exhibited significant anticancer activity, outperforming the reference drug, doxorubicin. A detailed molecular docking study for T7, T9, and doxorubicin was carried out using Autodock Vina software. The binding interactions were assessed by targeting the binding site groove of the human topoisomerase II alpha enzyme (PDB: ID:5GWK). The results revealed favorable RMSD values and strong binding patterns for the compounds, indicating their promising potential as inhibitors